Shares of Koninklijke DSM (OTCMKTS:RDSMY) have received a consensus rating of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $27.00.
A number of research firms have weighed in on RDSMY. Zacks Investment Research upgraded Koninklijke DSM from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a report on Thursday, October 19th. Deutsche Bank upgraded Koninklijke DSM from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Finally, ValuEngine downgraded Koninklijke DSM from a “buy” rating to a “hold” rating in a report on Friday, December 1st.
Koninklijke DSM (OTCMKTS:RDSMY) opened at $24.42 on Wednesday. The company has a market capitalization of $17,729.34, a P/E ratio of 30.54, a price-to-earnings-growth ratio of 2.66 and a beta of 1.34. The company has a current ratio of 2.18, a quick ratio of 1.54 and a debt-to-equity ratio of 0.37. Koninklijke DSM has a 52-week low of $15.73 and a 52-week high of $26.23.
Koninklijke DSM Company Profile
Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.